30
Participants
Start Date
January 18, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
Tislelizumab
Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
Carboplatin or Cisplatin
"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."
Surgery
Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
RECRUITING
the Affiliated Hospital of Qingdao University, Qingdao
The Affiliated Hospital of Qingdao University
OTHER